BOLETÍN HTA

30 / 76

HIPERTENSIÓN / 2017 / VOL. 22
30
Referencias
1. Encuesta Nacional de Salud Chile 2010
2. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89: 3A-9A.
3. Tamargo J, Caballero R, Gómez R, et al. Características farmacológicas de los ARAII. ¿Son todos iguales?. Rev Esp Cardiol Supl. 2006;6: 10C-24C
4. Böhm M, Mahfoud F, Werner C, et al. Cardiovascular protection: a break through to high risk patients. EHJ Supplements 2009;11 (Supplement F): F19-F26
5. Abraham HM, White M, White W. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and
other cardiovascular diseases. Drug Saf. 2015;38:33-54
6. Ministerio de Salud (Chile). Guía Clínica. Hipertensión Arterial Primaria o Esencial en personas de 15 años y más. Santiago: Minsal 2010.
7. Guía de práctica clínica dela ESH/ESC 2013 para el manejo de la hipertensión arterial. Rev Esp Cardiol 2013; 66(10): 880.e1-880.e64
8. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Report from the Panel Members Appointed to the Eight Joint
National Committee (JNC 8). JAMA. doi:10.1001/jama.2013.284427
9. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-
resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059-2068.
10. Makani H, Bangalore S, Desouza KA, et al. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials.
The BMJ. 2013;346:f360.
11. Whelton PK, Carey RM, Aronow WS, et al . 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure
in Adults, Journal of the American College of Cardiology (2017), doi: 10.1016/j.jacc.2017.11.006.
12. Leung A, Daskalopoulou S, Dasgupta K, et al Hypertension Canada’s 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of
Hypertension in Adults. Canadian Journal of Cardiology 33 (2017) 557e576.
13. Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartán predicts a slower
decrease in long-term renal function. Kidney Int. 2011;80:282-7.
14. Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery
stenosis in a solitary kidney. N Engl J Med. 1983;308:373-6.
15. Caldeira D, David C, Sampaio C. Tolerability of angiotensin receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors:
a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2012; 21: 263-77
16. Rubio-Tapia A, Hernan ML, Ludvigsson JF. Severe spruelike enteropathy associated with olmesartán. Mayo Clin Proc. 2012; 87:732-8
17. Greywoode R, Braunstein ED, Arguelles-Grande C, et al.. Olmesartán, other anti-hypertensives, and chronic diarrhea among patients undergoing
endoscopic procedures; a case-control study. Mayo Clinic Proceedings. 2014;89:1239-1243.
18. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled
trials. Lancet Oncol. 2010;11:627-636.
19. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168
participants from randomised trials. Lancet Oncol. 2011; 12:65-82.
20. Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential
analyses of 147020 patients from randomised trials. The BMJ. 2011;342:d2234..
21. Dahlof B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartán Intervention For Endpoint reduction
in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003.
22. Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group.- Outcomes inhypertensive patients at high cardiovascular risk treated with regimens based
on valsartán or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022–2031.
23. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind
intervention trial. J Hypertens 2003;21:875–886.